페이로니병의 치료에서 Potassium Aminobenzoate의 초기 경험

초록

Purpose: To evaluate the effect and improvement of potassium aminobenzoate (500 mg Peyron capsule) in oral therapy for Peyronie’s disease. Materials and Methods: From February 2011 to September 2011, 31 patients with Peyronie’s disease received potassium aminobezoate (500 mg Peyron capsules) and were divided into two groups. Group 1 (N=10) received potassium aminobezoate (500 mg Peyron capsule) 3 g four times daily without previous treatment of Peyronie’s disease, while group 2 (N=21) received the same drug with previous treatment of Peyronie’s disease (10 mg Tamoxifen＋300 mg L-carnitine two times daily). Outcomes were assessed by subjective symptom change, pain relief, resolutions of the plaque, and curvature. Results: After 3 months, there were no significant improvements in clinical outcomes of either group and among all the patients, 23 stopped taking potassium aminobezoate (23/31, 74%). The reasons for ceasing the therapy were gastrointestinal trouble (8/23, 35%), too many doses to take (7/23, 30%), ineffectiveness (6/23, 26%), and high price (2/23, 9%). Conclusions: Athough the etiology of Peyronie’s disease has not been elucidated, potassium aminobenzoate in therapy of Peyronie’s disease has been used. The use of this medication has the limitations of gastrointestinal trouble, ineffectiveness, too many doses, and high price. Further evaluations of the effect and appropriate dosing of potassium aminobenzoate are needed.

키워드